KR100777169B1 - 5-메틸-1-페닐-2-(1h)-피리돈을 활성 성분으로서함유하는 의약 제제 - Google Patents
5-메틸-1-페닐-2-(1h)-피리돈을 활성 성분으로서함유하는 의약 제제 Download PDFInfo
- Publication number
- KR100777169B1 KR100777169B1 KR1020037009856A KR20037009856A KR100777169B1 KR 100777169 B1 KR100777169 B1 KR 100777169B1 KR 1020037009856 A KR1020037009856 A KR 1020037009856A KR 20037009856 A KR20037009856 A KR 20037009856A KR 100777169 B1 KR100777169 B1 KR 100777169B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- pirfenidone
- tablet
- delete delete
- tablets
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
성분 | 양 | 주(註) |
피르페니돈 | 200.0 mg | |
락토오스 | 56.0 mg | |
카르멜로스 칼슘 | 20.0 mg | 과립내: 5.0 mg 과립외: 15.0 mg |
히드록시프로필셀룰로오스 | 6.0 mg | |
스테아르산마그네슘 | 3.0 mg | |
플레인 정제의 총 중량 285.0 mg | ||
히드록시프로필메틸셀룰로오스 2910 | 6.67 mg | |
산화티탄 | 2.66 mg | |
트리에틸 시트레이트 | 0.67 mg | |
스테아르산마그네슘 | 미량 | 0.02 mg |
활석 | 미량 | 0.02 mg |
코팅의 총 중량 10.00 mg | ||
코팅 정제의 총 중량 295.0 mg |
표본 | 색상차 (ΔE) | 변색 |
약물 물질 | 0.73 | 약간 |
압착 약물 물질 | 3.62 | 현저함 |
플레인 정제 | 5.08 | 현저함 |
코팅 정제 | 0.75 | 약간 |
Claims (14)
- 5-메틸-1-페닐-2-(1H)-피리돈을 주성분으로 함유하는 정제로서,상기 주성분의 함량이 200 mg이고, 56 mg의 락토오스, 20 mg의 카르멜로스 칼슘, 6.0 mg의 히드록시프로필셀룰로오스 및 3 mg의 스테아르산마그네슘을 함유하는 플레인 정제, 및 6.67 mg의 히드록시프로필메틸셀룰로오스, 0.67 mg의 트리에틸 시트레이트 및 2.66 mg의 산화티탄을 함유하는 코팅층으로 이루어지는 정제.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001019393 | 2001-01-29 | ||
JPJP-P-2001-00019393 | 2001-01-29 | ||
PCT/JP2002/000544 WO2002060446A1 (en) | 2001-01-29 | 2002-01-25 | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020077018953A Division KR100891887B1 (ko) | 2001-01-29 | 2002-01-25 | 5-메틸-1-페닐-2-(1h)-피리돈을 활성 성분으로서 함유하는의약 제제 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030072608A KR20030072608A (ko) | 2003-09-15 |
KR100777169B1 true KR100777169B1 (ko) | 2007-11-16 |
Family
ID=18885277
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020077018953A KR100891887B1 (ko) | 2001-01-29 | 2002-01-25 | 5-메틸-1-페닐-2-(1h)-피리돈을 활성 성분으로서 함유하는의약 제제 |
KR1020037009856A KR100777169B1 (ko) | 2001-01-29 | 2002-01-25 | 5-메틸-1-페닐-2-(1h)-피리돈을 활성 성분으로서함유하는 의약 제제 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020077018953A KR100891887B1 (ko) | 2001-01-29 | 2002-01-25 | 5-메틸-1-페닐-2-(1h)-피리돈을 활성 성분으로서 함유하는의약 제제 |
Country Status (8)
Country | Link |
---|---|
US (7) | US7867516B2 (ko) |
EP (1) | EP1356816B1 (ko) |
JP (1) | JP4077320B2 (ko) |
KR (2) | KR100891887B1 (ko) |
AT (1) | ATE452637T1 (ko) |
DE (1) | DE60234812D1 (ko) |
TW (1) | TWI314868B (ko) |
WO (1) | WO2002060446A1 (ko) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002060446A1 (en) | 2001-01-29 | 2002-08-08 | Shionogi & Co., Ltd. | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
EP1673064A1 (en) * | 2003-08-28 | 2006-06-28 | Sandoz AG | Pharmaceutical composition comprising anticonvulsant with taste mask coating |
JP2005187339A (ja) * | 2003-12-24 | 2005-07-14 | Iwaki Seiyaku Co Ltd | 耐光性塩酸テルビナフィンフィルムコート錠 |
EA015252B1 (ru) | 2005-05-10 | 2011-06-30 | Интермьюн, Инк. | Способ модуляции стресс-активированной протеинкиназной системы |
NZ591443A (en) † | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
US20070203202A1 (en) * | 2005-12-02 | 2007-08-30 | Robinson Cynthia Y | Methods of reducing adverse events associated with pirfenidone therapy |
CA2667654C (en) * | 2006-12-18 | 2016-12-13 | Intermune, Inc. | Method of providing pirfenidone therapy to a patient |
US20080287508A1 (en) * | 2007-05-18 | 2008-11-20 | Intermune, Inc. | Altering pharmacokinetics of pirfenidone therapy |
JP5248040B2 (ja) | 2007-05-25 | 2013-07-31 | リードケミカル株式会社 | 5−メチル−1−フェニル−2−(1h)−ピリドン含有貼付剤 |
MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
CN102099036B (zh) | 2008-06-03 | 2015-05-27 | 英特芒尼公司 | 用于治疗炎性疾患和纤维化疾患的化合物和方法 |
JP2010120912A (ja) | 2008-11-21 | 2010-06-03 | Lead Chemical Co Ltd | 5−メチル−1−フェニル−2−(1h)−ピリドン含有貼付剤 |
CN105878242A (zh) | 2009-04-01 | 2016-08-24 | 巴尔-波特拉及康邦亚股份有限公司 | 包括硝基儿茶酚衍生物的药物制剂及其制备方法 |
WO2010114405A2 (en) * | 2009-04-01 | 2010-10-07 | Bial - Portela & Ca., S.A. | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same |
CN101972236A (zh) * | 2010-10-13 | 2011-02-16 | 北京诚创康韵医药科技有限公司 | 一种含吡非尼酮的缓释制剂 |
US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
AU2012212269B2 (en) | 2011-01-31 | 2016-05-19 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
MX2011007675A (es) * | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
EP2744498A4 (en) * | 2012-02-16 | 2014-12-03 | Teva Pharma | N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-CHINOLINE CARBOXAMIDE AND THE PREPARATION AND USE THEREOF |
MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
KR101453688B1 (ko) * | 2013-11-05 | 2014-11-04 | 포항공과대학교 산학협력단 | 광 입사 각도 선택성을 가지는 전자 소자 및 그 제조 방법 |
NZ722927A (en) | 2014-01-10 | 2022-07-29 | Avalyn Pharma Inc | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
CN110452216B (zh) | 2014-04-02 | 2022-08-26 | 英特穆恩公司 | 抗纤维化吡啶酮类 |
CA2937365C (en) * | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
TWI745396B (zh) | 2016-07-12 | 2021-11-11 | 日商鹽野義製藥股份有限公司 | 吸入用醫藥組成物 |
MX364040B (es) * | 2016-11-11 | 2019-04-11 | Cell Therapy And Tech S A De C V | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash). |
JP7191446B2 (ja) | 2017-01-30 | 2022-12-19 | 塩野義製薬株式会社 | キナゾリン誘導体を含有する固形製剤 |
KR20180100869A (ko) * | 2017-03-02 | 2018-09-12 | 영진약품 주식회사 | 피르페니돈의 입자크기 조절에 따른 타정성이 개선된 약제학적 조성물 및 이의 제조방법 |
CN109223723B (zh) * | 2017-07-11 | 2021-08-27 | 南京华威医药科技集团有限公司 | 吡非尼酮片剂及其制备方法和用途 |
MX366086B (es) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel. |
TWI795462B (zh) | 2017-11-17 | 2023-03-11 | 日商鹽野義製藥股份有限公司 | 光安定性及溶出性優異的醫藥製劑 |
ES2900457T3 (es) | 2018-01-12 | 2022-03-17 | Tiefenbacher Alfred E Gmbh & Co Kg | Formulación de comprimidos y cápsulas que contienen pirfenidona |
KR102584268B1 (ko) * | 2020-04-22 | 2023-10-05 | 영진약품 주식회사 | 안전성과 안정성이 개선된 피르페니돈을 포함하는 장용성 제제 및 이의 제조방법 |
WO2023161668A1 (en) | 2022-02-28 | 2023-08-31 | Nuformix Technologies Limited | Compositions and methods for treatment of idiopathic pulmonary fibrosis |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3974281A (en) | 1972-12-18 | 1976-08-10 | Affiliated Medical Research, Inc. | 5-Methyl-1-phenyl-2-(1H)-pyridone compositions and methods of use |
EP0901787A1 (en) * | 1997-09-10 | 1999-03-17 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4042699A (en) | 1972-12-18 | 1977-08-16 | Affiliated Medical Research, Inc. | Method for reducing serum glucose levels |
US4052509A (en) | 1972-12-18 | 1977-10-04 | Affiliated Medical Research, Inc. | Method for reducing serum uric acid levels |
CA1261835A (en) | 1984-08-20 | 1989-09-26 | Masaaki Toda | (fused) benz(thio)amides |
US4753801A (en) * | 1985-10-25 | 1988-06-28 | Eli Lilly And Company | Sustained release tablets |
US5271946A (en) * | 1988-04-20 | 1993-12-21 | Asta Pharma Aktiengesellschaft | Controlled release azelastine-containing pharmaceutical compositions |
JPH02215719A (ja) | 1989-02-15 | 1990-08-28 | Yamauchi Akitomo | 線維化病変組織の修復並びに線維化病変の阻止剤 |
US5716632A (en) * | 1989-11-22 | 1998-02-10 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
US5518729A (en) | 1989-11-22 | 1996-05-21 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
US5310562A (en) * | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
WO1994026249A1 (en) * | 1993-05-07 | 1994-11-24 | Margolin Solomon B | Compositions and methods for reparation and prevention of fibrotic lesions |
WO1995006462A1 (en) * | 1993-08-30 | 1995-03-09 | Warner-Lambert Company | Tablet coating based on a melt-spun mixture of a saccharide and apolymer |
US5591766A (en) * | 1993-12-03 | 1997-01-07 | Cheil Foods & Chemicals, Inc. | Solid oral formulations of pyridone carboxylic acids |
US5639754A (en) | 1994-07-12 | 1997-06-17 | Janssen Pharmaceutica N.V. | Urea and thiourea derivatives of azolones |
US6107458A (en) | 1994-10-07 | 2000-08-22 | Fujisawa Pharmaceutical Co., Ltd. | Cyclic hexapeptides having antibiotic activity |
US6090822A (en) | 1995-03-03 | 2000-07-18 | Margolin; Solomon B. | Treatment of cytokine growth factor caused disorders |
DK0837052T3 (da) | 1995-06-21 | 2007-01-02 | Shionogi & Co | Bicykliske aminoderivater og PGD2-antagonist indeholdende disse |
JPH091787A (ja) * | 1995-06-22 | 1997-01-07 | Canon Inc | 印字装置 |
US5681382A (en) * | 1995-08-22 | 1997-10-28 | Shin-Etsu Chemical Co., Ltd. | Rapidly soluble coating composition and method for preparing same |
US5962478A (en) | 1995-09-19 | 1999-10-05 | Margolin; Solomon B. | Inhibition of tumor necrosis factor α |
AU709178B2 (en) * | 1995-09-19 | 1999-08-26 | Intermune, Inc. | Inhibition of tumor necrosis factor alpha |
TW580397B (en) * | 1997-05-27 | 2004-03-21 | Takeda Chemical Industries Ltd | Solid preparation |
CN1195500C (zh) * | 1998-05-18 | 2005-04-06 | 武田药品工业株式会社 | 可口腔崩解的片剂 |
AU3402301A (en) | 2000-03-07 | 2001-09-17 | Ranbaxy Laboratories Limited | Azole compounds as therapeutic agents for fungal infections |
EP1269995A1 (en) | 2000-03-27 | 2003-01-02 | Kyowa Hakko Kogyo Co., Ltd. | Easy-to-take granule |
KR20030024799A (ko) | 2000-07-20 | 2003-03-26 | 뉴로젠 코포레이션 | 캡사이신 수용체 리간드 |
US20040034039A1 (en) | 2000-09-22 | 2004-02-19 | Yoshinori Nakano | Solid preparations |
WO2002060446A1 (en) * | 2001-01-29 | 2002-08-08 | Shionogi & Co., Ltd. | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
MXPA03009353A (es) | 2001-04-12 | 2004-02-12 | Pharmacopeia Inc | Aril y biaril piperidinas utilizadas como antagonistas de mch. |
WO2002087549A1 (fr) | 2001-04-25 | 2002-11-07 | Taisho Pharmaceutical Co., Ltd. | Comprimes a liberation prolongee du type a unites multiples |
AU2002352878B2 (en) | 2001-11-27 | 2007-11-22 | Merck Sharp & Dohme Corp. | 2-Aminoquinoline compounds |
ES2345044T3 (es) | 2002-02-01 | 2010-09-14 | Euro-Celtique S.A. | 2-piperazin-piridinas utiles para tratar el dolor. |
US6974818B2 (en) | 2002-03-01 | 2005-12-13 | Euro-Celtique S.A. | 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain |
WO2004002983A2 (en) | 2002-06-28 | 2004-01-08 | Euro-Celtique, S.A. | Therapeutic piperazine derivatives useful for treating pain |
US7262194B2 (en) | 2002-07-26 | 2007-08-28 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
CA2496314A1 (en) | 2002-08-27 | 2004-03-11 | Intermune, Inc. | Methods of treating idiopathic pulmonary fibrosis |
CA2496577A1 (en) | 2002-08-28 | 2004-03-11 | Intermune, Inc. | Combination therapy for treatment of fibrotic disorders |
US7157462B2 (en) | 2002-09-24 | 2007-01-02 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
JP2006505570A (ja) | 2002-10-17 | 2006-02-16 | アムジエン・インコーポレーテツド | ベンズイミダゾール誘導体およびそれのバニロイド受容体リガンドとしての使用 |
US7582635B2 (en) | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
RS20050714A (sr) | 2003-03-31 | 2008-04-04 | Pliva-Lachema A.S., | Farmaceutski preparati koji kao aktivnu suptancu sadrže kompleks platine i postupci za njihovo dobijanje |
US20050008691A1 (en) | 2003-05-14 | 2005-01-13 | Arturo Siles Ortega | Bicalutamide compositions |
WO2004103296A2 (en) | 2003-05-16 | 2004-12-02 | Intermune, Inc. | Methods of treating idiopathic pulmonary fibrosis |
WO2005016241A2 (en) | 2003-05-16 | 2005-02-24 | Intermune, Inc. | Synthetic chemokine receptor ligands and methods of use thereof |
MY142655A (en) | 2003-06-12 | 2010-12-15 | Euro Celtique Sa | Therapeutic agents useful for treating pain |
WO2005004763A1 (en) | 2003-07-01 | 2005-01-20 | Pharmacia & Upjohn Company Llc. | Diffusion layer modulated solids |
GEP20094676B (en) | 2003-07-24 | 2009-05-10 | Euro Celtique Sa | Piperidine compounds and pharmaceutical compositions containing them |
EA009480B1 (ru) | 2003-07-24 | 2008-02-28 | Еуро-Селтик С. А. | Гетероарил-тетрагидропиридины и их применение для лечения или профилактики боли |
DE602004025244D1 (de) | 2003-08-01 | 2010-03-11 | Euro Celtique Sa | Zur behandlung von schmerzen geeignete therapeutische mittel |
DE602004017481D1 (de) | 2003-09-22 | 2008-12-11 | Euro Celtique Sa | Zur behandlung von schmerzen geeignete therapeutische mittel |
CN1856489A (zh) | 2003-09-22 | 2006-11-01 | 欧洲凯尔特公司 | 用于治疗疼痛的苯甲酰胺化合物 |
US7407973B2 (en) | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
EP1683788B1 (en) | 2003-11-14 | 2012-03-21 | Shanghai Genomics, Inc. | Derivatives of pyridone and use thereof |
US7592373B2 (en) | 2003-12-23 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds |
RS50958B (sr) | 2003-12-30 | 2010-10-31 | Euro-Celtique S.A. | Piperazini korisni za lečenje bola |
SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
US8642079B2 (en) | 2004-02-23 | 2014-02-04 | Hormos Medical Corporation | Solid formulations of ospemifene |
US7605176B2 (en) | 2004-03-06 | 2009-10-20 | Boehringer Ingelheim International Gmbh | β-ketoamide compounds with MCH antagonistic activity |
WO2005115990A1 (ja) | 2004-05-26 | 2005-12-08 | Eisai R & D Management Co., Ltd. | シンナミド化合物 |
EP2305696A3 (en) | 2005-07-25 | 2011-10-12 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
NZ591443A (en) | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
EP1959944A1 (en) | 2005-12-15 | 2008-08-27 | Shionogi Co., Ltd. | A pharmaceutical composition comprising an amide derivative |
CA2833209C (en) | 2007-04-27 | 2016-06-28 | Purdue Pharma L.P. | Piperidine and piperazine compounds as trpv1 antagonists |
US8389549B2 (en) | 2007-04-27 | 2013-03-05 | Purdue Pharma L.P. | Substituted pyridines useful for treating pain |
JP2011518144A (ja) | 2008-04-17 | 2011-06-23 | ファイザー・インク | Faah阻害剤として有用な4−ベンジリデン−3−メチルピペリジンアリールカルボキサミド化合物 |
EP2296659B1 (en) | 2008-06-05 | 2016-12-21 | Janssen Pharmaceutica, N.V. | Drug combinations comprising a DGAT inhibitor and a PPAR-agonist |
US8759362B2 (en) | 2008-10-24 | 2014-06-24 | Purdue Pharma L.P. | Bicycloheteroaryl compounds and their use as TRPV1 ligands |
US8703962B2 (en) | 2008-10-24 | 2014-04-22 | Purdue Pharma L.P. | Monocyclic compounds and their use as TRPV1 ligands |
US8546388B2 (en) | 2008-10-24 | 2013-10-01 | Purdue Pharma L.P. | Heterocyclic TRPV1 receptor ligands |
US8921373B2 (en) | 2010-06-22 | 2014-12-30 | Shionogi & Co., Ltd. | Compounds having TRPV1 antagonistic activity and uses thereof |
-
2002
- 2002-01-25 WO PCT/JP2002/000544 patent/WO2002060446A1/ja active Application Filing
- 2002-01-25 EP EP02710352A patent/EP1356816B1/en not_active Expired - Lifetime
- 2002-01-25 DE DE60234812T patent/DE60234812D1/de not_active Expired - Lifetime
- 2002-01-25 KR KR1020077018953A patent/KR100891887B1/ko active IP Right Grant
- 2002-01-25 AT AT02710352T patent/ATE452637T1/de not_active IP Right Cessation
- 2002-01-25 JP JP2002560638A patent/JP4077320B2/ja not_active Expired - Fee Related
- 2002-01-25 US US10/470,334 patent/US7867516B2/en not_active Expired - Lifetime
- 2002-01-25 KR KR1020037009856A patent/KR100777169B1/ko active IP Right Grant
- 2002-01-29 TW TW091101440A patent/TWI314868B/zh not_active IP Right Cessation
-
2010
- 2010-11-08 US US12/941,994 patent/US20110104276A1/en not_active Abandoned
-
2011
- 2011-12-21 US US13/333,142 patent/US20120183615A1/en not_active Abandoned
-
2012
- 2012-10-26 US US13/662,221 patent/US9017722B2/en not_active Expired - Fee Related
-
2015
- 2015-03-27 US US14/671,251 patent/US20150209341A1/en not_active Abandoned
- 2015-11-24 US US14/951,313 patent/US9561217B2/en not_active Expired - Lifetime
-
2016
- 2016-12-20 US US15/385,451 patent/US20170100380A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3974281A (en) | 1972-12-18 | 1976-08-10 | Affiliated Medical Research, Inc. | 5-Methyl-1-phenyl-2-(1H)-pyridone compositions and methods of use |
EP0901787A1 (en) * | 1997-09-10 | 1999-03-17 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
Also Published As
Publication number | Publication date |
---|---|
ATE452637T1 (de) | 2010-01-15 |
KR20030072608A (ko) | 2003-09-15 |
US9017722B2 (en) | 2015-04-28 |
US20110104276A1 (en) | 2011-05-05 |
US20130115288A1 (en) | 2013-05-09 |
US20120183615A1 (en) | 2012-07-19 |
US9561217B2 (en) | 2017-02-07 |
KR20070093006A (ko) | 2007-09-14 |
EP1356816A1 (en) | 2003-10-29 |
WO2002060446A1 (en) | 2002-08-08 |
EP1356816B1 (en) | 2009-12-23 |
JP4077320B2 (ja) | 2008-04-16 |
US7867516B2 (en) | 2011-01-11 |
US20150209341A1 (en) | 2015-07-30 |
DE60234812D1 (de) | 2010-02-04 |
TWI314868B (en) | 2009-09-21 |
US20040048902A1 (en) | 2004-03-11 |
KR100891887B1 (ko) | 2009-04-03 |
EP1356816A4 (en) | 2005-02-09 |
US20170100380A1 (en) | 2017-04-13 |
US20160074375A1 (en) | 2016-03-17 |
JPWO2002060446A1 (ja) | 2004-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100777169B1 (ko) | 5-메틸-1-페닐-2-(1h)-피리돈을 활성 성분으로서함유하는 의약 제제 | |
JP4638561B2 (ja) | プロトンポンプ抑制剤を含有するマルチプルユニットの沸騰剤形 | |
JP6092936B2 (ja) | 口腔内崩壊錠の製造方法 | |
JP4638964B2 (ja) | プロトンポンプ阻害剤およびnsaidからなる経口用医薬剤形 | |
JP4435424B2 (ja) | 口腔内で速やかに崩壊する錠剤 | |
US20060153925A1 (en) | Novel solid pharmaceutical composition comprising amisulpride | |
JP6037840B2 (ja) | 口腔内崩壊錠 | |
KR20040098009A (ko) | 구강 내 속붕괴성 정제 | |
EP0749308B1 (en) | Film coated tablet of paracetamol and domperidone | |
JP2009256344A (ja) | プロトンポンプ阻害剤を含有する被覆微粒子 | |
JPWO2007074910A1 (ja) | 放出制御固形製剤 | |
CZ280847B6 (cs) | Peroorálně aplikovatelná forma léku pro léčení centrálních stavů nedostatku dopaminu | |
US20060159758A1 (en) | Coating composition for taste masking coating and methods for their application and use | |
KR100846945B1 (ko) | 파라세타몰을 포함하는 연하 정제 | |
RU2108097C1 (ru) | Фармацевтическая композиция, содержащая соль ранитидина и карбоксилата висмута, и способ ее получения | |
JP4549609B2 (ja) | 被覆固形催眠製剤 | |
WO2019199136A1 (ko) | 붕해가 개선된 레날리도마이드의 경구용 정제 조성물 | |
JPS6360926A (ja) | 感冒薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
A107 | Divisional application of patent | ||
AMND | Amendment | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
G170 | Re-publication after modification of scope of protection [patent] | ||
FPAY | Annual fee payment |
Payment date: 20121023 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20131022 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20141021 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20151016 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20161020 Year of fee payment: 10 |
|
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2016100003492; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161104 Effective date: 20170623 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2016100003634; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161118 Effective date: 20170623 |
|
J206 | Request for trial to confirm the scope of a patent right | ||
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2017100001656; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170531 Effective date: 20170905 |
|
FPAY | Annual fee payment |
Payment date: 20171018 Year of fee payment: 11 |
|
J206 | Request for trial to confirm the scope of a patent right | ||
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2017100001819; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170614 Effective date: 20180321 Free format text: TRIAL NUMBER: 2017100002482; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170807 Effective date: 20180321 |
|
J206 | Request for trial to confirm the scope of a patent right | ||
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2018100000190; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20180118 Effective date: 20180419 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2018100001063; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20180405 Effective date: 20180723 |
|
FPAY | Annual fee payment |
Payment date: 20181023 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20191017 Year of fee payment: 13 |